Hemostasis Market Report and Forecast 2025-2034
Description
The global hemostasis market was valued at USD 3.70 Billion in 2024, driven by the growing number of surgical procedures across the globe. The market is anticipated to grow at a CAGR of 3.40% during the forecast period 2025-2034 to reach a value of USD 5.17 Billion by 2034.
Hemostasis Market Overview
Hemostasis is the body’s reaction to heal an injury that caused bleeding in the first place. The capability of the body to heal itself plays a vital role in the survival of a person. The reaction is a combination of multiple processes coming together to heal a wound. The market for hemostasis is driven by the rising incidence of surgical procedures, new product launches developed using innovative materials and the rising prevalence of accidents on a global scale. Conditions like hemophilia and von Willebrand disease are driving the need for advanced hemostasis solutions, leading to increased R&D for better treatments.
Hemostasis Market Growth Drivers
Rising Surgical Procedures Contributing to Rising Demand for Hemostasis Management
The market growth can be attributed to the escalating number of surgeries across several fields including cardiovascular and trauma surgeries. As per the data published by the Annals of Thoracic Surgery Short Reports, the average cardiac surgical volume is around 123.2 surgeries per 100,000 population per year in high-income countries. Similarly, surgeries for other chronic diseases are increasing, creating a high demand for hemostasis agents, and stimulating market growth.
Increasing Approvals to Meet Rising Hemostasis Market Demand
The market growth is poised to be driven by the increasing FDA approvals, enabling the availability of multiple hemostasis solutions contributing to enhanced patient outcomes. For instance, in November 2023, Ethicon, a Johnson & Johnson MedTech company, announced the approval of ETHIZIATM, an adjunctive hemostasis solution that has been clinically proven to achieve sustained hemostasis in difficult-to-control bleeding situations. ETHIZIA™ Hemostatic Sealing Patch is comprised of unique synthetic polymer technology and is the first and only hemostatic matrix designed to be equally active and efficacious on both sides.
Additionally, in April 2024, Haemonetics Corporation, a global medical technology company focused on delivering innovative medical solutions to drive better patient outcomes, announced the 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the TEG® 6s hemostasis analyzer system Global Hemostasis-HN assay cartridge. This new cartridge extends Haemonetics' TEG 6s viscoelastic testing capabilities to serve fully heparinized patients in adult cardiovascular surgeries/procedures and liver transplantation in both laboratory and point-of-care settings. This product launch is expected to assist physicians in improving hemostasis management for their patients, especially in critical situations like open heart and liver transplant surgeries and major trauma. The FDA clearance is also projected to make effective and efficient viscoelastic testing more accessible, contributing to market expansion.
Hemostasis Market Trends
The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:
Technological Advancements
The market is experiencing growing adoption of point-of-care (POC) testing and automated devices, improving accuracy and speed in diagnosing and managing bleeding disorders. These advanced devices are poised to bring innovation to the hemostasis landscape.
Product Launches Propelling Market Growth
One of the major market trends involves new product launches. For instance, in July 2024, Baxter International Inc., a global leader in advancing surgical innovation launched PERCLOT Absorbable Hemostatic Powder in the United States. PERCLOT is a passive, absorbable hemostatic powder designed to be used by patients with intact coagulation to address mild bleeding. New product launches are poised to fuel market growth, contributing to enhanced patient outcomes.
Advanced Hemostatic Agents
With rising surgical procedures and trauma cases, the demand for advanced hemostatic agents, such as tissue sealants and fibrin adhesives, is increasing globally. Key players are developing novel products such as fibrin sealants, collagen-based agents, gelatin sponges, and synthetic sealants. These products offer rapid clotting and tissue adhesion properties, enhancing surgical outcomes.
Growth in Minimally Invasive Surgeries
There is a growing preference for minimally invasive surgeries driven by its faster recovery times and reduced complications. With more minimally invasive surgeries being performed, specialised hemostatic products that aid in faster recovery and reduced blood loss are in higher demand.
Hemostasis Market Segmentation
Market Breakup by Product Type
Market Share Based on Application to Witness Substantial Growth
The market segmentation by application is categorised into general surgery, neurosurgery, vascular surgery, cardiovascular surgery, and others. The market share is dominated by general surgeries due to the high incidence worldwide. Hemostatic management plays a vital role in surgical procedures to control the blood flow and avoid excessive bleeding during and after the procedures. These hemostat agents have common applications in advanced surgical procedures that necessitate effective tissue-sealing agents to eliminate or reduce complications and result in improved patient outcomes. The similar nature of collagen-based hemostats to the collagen in the tissue makes them a preferred option to be used in these surgeries.
Hemostasis Market Analysis by Region
North America is dominating the market share by region due to the rising cases of excessive bleeding and the need to bring new solutions for hemostasis management. The market is poised to be driven by the presence of a robust healthcare infrastructure, enabling the availability of technically advanced management solutions. Further, the presence of some of the key players in the region is stimulating market growth. The region leads the hemostats market due to significant healthcare expenditure, and the presence of major pharmaceutical and medical device companies that are focused on bringing innovation into the market.
The region experiences a high volume of surgical procedures, and trauma cases, and also holds a significant share of the geriatric population contributing to increased demand for hemostatic products. Additionally, strong regulatory frameworks and rapid adoption of advanced medical technologies, such as minimally invasive surgical tools and point-of-care hemostasis testing, further fuel the market. The regional dominance is also attributed to the continuous focus on product innovation and widespread insurance coverage supporting growth in the market.
Leading Players in the Hemostasis Market
The key features of the market report comprise patent analysis, grants analysis, funding and investment analysis and strategic initiatives by the leading players. The major companies in the market are as follows:
Medtronic PLC
Medtronic offers a range of hemostatic products, including advanced surgical sealants, topical agents, and mechanical haemostats. Its portfolio focuses on managing bleeding during surgeries, enhancing wound healing, and improving patient recovery through innovative medical technologies across cardiovascular, neuro, and general surgeries.
Johnson & Johnson Inc.
Johnson & Johnson, through its subsidiary Ethicon, provides a comprehensive portfolio of hemostatic products including SURGIFLO®, SURGICEL®, and EVARREST®. These products are designed to control bleeding in surgical settings, ensuring rapid hemostasis and improved patient outcomes across various surgical procedures.
Baxter International Inc.
Baxter is a key player in the hemostasis market, offering products like Floseal® and Tisseel®. These haemostatic agents are used in surgical procedures to control bleeding, combining biological and mechanical hemostasis for optimal surgical outcomes, supporting vascular, orthopaedic, and general surgery applications.
Pfizer
Pfizer's presence in the hemostasis market is primarily through its biologics division, offering recombinant clotting factors, such as BeneFIX®, for the treatment of haemophilia. The company focuses on therapies that enhance blood clotting for patients with clotting disorders, supporting both surgical and non-surgical applications.
BD
BD focuses on hemostasis through its range of vascular access devices, blood collection systems, and point-of-care diagnostics. Its products help manage blood flow, improve blood sampling, and enhance patient safety in various clinical settings, from surgery to emergency care.
Other key players in the market include B. Braun SE, Tricol Biomedical, Boston Scientific Corporation, Cura Medical, and Teleflex Incorporated.
Key Questions Answered in the Hemostasis Market
Hemostasis Market Overview
Hemostasis is the body’s reaction to heal an injury that caused bleeding in the first place. The capability of the body to heal itself plays a vital role in the survival of a person. The reaction is a combination of multiple processes coming together to heal a wound. The market for hemostasis is driven by the rising incidence of surgical procedures, new product launches developed using innovative materials and the rising prevalence of accidents on a global scale. Conditions like hemophilia and von Willebrand disease are driving the need for advanced hemostasis solutions, leading to increased R&D for better treatments.
Hemostasis Market Growth Drivers
Rising Surgical Procedures Contributing to Rising Demand for Hemostasis Management
The market growth can be attributed to the escalating number of surgeries across several fields including cardiovascular and trauma surgeries. As per the data published by the Annals of Thoracic Surgery Short Reports, the average cardiac surgical volume is around 123.2 surgeries per 100,000 population per year in high-income countries. Similarly, surgeries for other chronic diseases are increasing, creating a high demand for hemostasis agents, and stimulating market growth.
Increasing Approvals to Meet Rising Hemostasis Market Demand
The market growth is poised to be driven by the increasing FDA approvals, enabling the availability of multiple hemostasis solutions contributing to enhanced patient outcomes. For instance, in November 2023, Ethicon, a Johnson & Johnson MedTech company, announced the approval of ETHIZIATM, an adjunctive hemostasis solution that has been clinically proven to achieve sustained hemostasis in difficult-to-control bleeding situations. ETHIZIA™ Hemostatic Sealing Patch is comprised of unique synthetic polymer technology and is the first and only hemostatic matrix designed to be equally active and efficacious on both sides.
Additionally, in April 2024, Haemonetics Corporation, a global medical technology company focused on delivering innovative medical solutions to drive better patient outcomes, announced the 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the TEG® 6s hemostasis analyzer system Global Hemostasis-HN assay cartridge. This new cartridge extends Haemonetics' TEG 6s viscoelastic testing capabilities to serve fully heparinized patients in adult cardiovascular surgeries/procedures and liver transplantation in both laboratory and point-of-care settings. This product launch is expected to assist physicians in improving hemostasis management for their patients, especially in critical situations like open heart and liver transplant surgeries and major trauma. The FDA clearance is also projected to make effective and efficient viscoelastic testing more accessible, contributing to market expansion.
Hemostasis Market Trends
The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:
Technological Advancements
The market is experiencing growing adoption of point-of-care (POC) testing and automated devices, improving accuracy and speed in diagnosing and managing bleeding disorders. These advanced devices are poised to bring innovation to the hemostasis landscape.
Product Launches Propelling Market Growth
One of the major market trends involves new product launches. For instance, in July 2024, Baxter International Inc., a global leader in advancing surgical innovation launched PERCLOT Absorbable Hemostatic Powder in the United States. PERCLOT is a passive, absorbable hemostatic powder designed to be used by patients with intact coagulation to address mild bleeding. New product launches are poised to fuel market growth, contributing to enhanced patient outcomes.
Advanced Hemostatic Agents
With rising surgical procedures and trauma cases, the demand for advanced hemostatic agents, such as tissue sealants and fibrin adhesives, is increasing globally. Key players are developing novel products such as fibrin sealants, collagen-based agents, gelatin sponges, and synthetic sealants. These products offer rapid clotting and tissue adhesion properties, enhancing surgical outcomes.
Growth in Minimally Invasive Surgeries
There is a growing preference for minimally invasive surgeries driven by its faster recovery times and reduced complications. With more minimally invasive surgeries being performed, specialised hemostatic products that aid in faster recovery and reduced blood loss are in higher demand.
Hemostasis Market Segmentation
Market Breakup by Product Type
- Topical Hemostasis Products
- Gelatin-based Hemostats
- Collagen-based Hemostats
- ORC-based Hemostats
- Polysaccharide-based
- Infusible Hemostasis Products
- Platelet Concentrate
- Fresh Frozen Plasma
- Factor VIII
- Prothrombin
- Advanced Hemostasis Products
- Flowable
- Thrombin
- Synthetic Sealants
- Fibrin
- General Surgery
- Neurosurgery
- Vascular Surgery
- Cardiovascular Surgery
- Others
- Hospitals
- Specialty Clinics
- Ambulatory Surgical Centers
- Others
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
Market Share Based on Application to Witness Substantial Growth
The market segmentation by application is categorised into general surgery, neurosurgery, vascular surgery, cardiovascular surgery, and others. The market share is dominated by general surgeries due to the high incidence worldwide. Hemostatic management plays a vital role in surgical procedures to control the blood flow and avoid excessive bleeding during and after the procedures. These hemostat agents have common applications in advanced surgical procedures that necessitate effective tissue-sealing agents to eliminate or reduce complications and result in improved patient outcomes. The similar nature of collagen-based hemostats to the collagen in the tissue makes them a preferred option to be used in these surgeries.
Hemostasis Market Analysis by Region
North America is dominating the market share by region due to the rising cases of excessive bleeding and the need to bring new solutions for hemostasis management. The market is poised to be driven by the presence of a robust healthcare infrastructure, enabling the availability of technically advanced management solutions. Further, the presence of some of the key players in the region is stimulating market growth. The region leads the hemostats market due to significant healthcare expenditure, and the presence of major pharmaceutical and medical device companies that are focused on bringing innovation into the market.
The region experiences a high volume of surgical procedures, and trauma cases, and also holds a significant share of the geriatric population contributing to increased demand for hemostatic products. Additionally, strong regulatory frameworks and rapid adoption of advanced medical technologies, such as minimally invasive surgical tools and point-of-care hemostasis testing, further fuel the market. The regional dominance is also attributed to the continuous focus on product innovation and widespread insurance coverage supporting growth in the market.
Leading Players in the Hemostasis Market
The key features of the market report comprise patent analysis, grants analysis, funding and investment analysis and strategic initiatives by the leading players. The major companies in the market are as follows:
Medtronic PLC
Medtronic offers a range of hemostatic products, including advanced surgical sealants, topical agents, and mechanical haemostats. Its portfolio focuses on managing bleeding during surgeries, enhancing wound healing, and improving patient recovery through innovative medical technologies across cardiovascular, neuro, and general surgeries.
Johnson & Johnson Inc.
Johnson & Johnson, through its subsidiary Ethicon, provides a comprehensive portfolio of hemostatic products including SURGIFLO®, SURGICEL®, and EVARREST®. These products are designed to control bleeding in surgical settings, ensuring rapid hemostasis and improved patient outcomes across various surgical procedures.
Baxter International Inc.
Baxter is a key player in the hemostasis market, offering products like Floseal® and Tisseel®. These haemostatic agents are used in surgical procedures to control bleeding, combining biological and mechanical hemostasis for optimal surgical outcomes, supporting vascular, orthopaedic, and general surgery applications.
Pfizer
Pfizer's presence in the hemostasis market is primarily through its biologics division, offering recombinant clotting factors, such as BeneFIX®, for the treatment of haemophilia. The company focuses on therapies that enhance blood clotting for patients with clotting disorders, supporting both surgical and non-surgical applications.
BD
BD focuses on hemostasis through its range of vascular access devices, blood collection systems, and point-of-care diagnostics. Its products help manage blood flow, improve blood sampling, and enhance patient safety in various clinical settings, from surgery to emergency care.
Other key players in the market include B. Braun SE, Tricol Biomedical, Boston Scientific Corporation, Cura Medical, and Teleflex Incorporated.
Key Questions Answered in the Hemostasis Market
- What was the global hemostasis market value in 2024?
- What is the global hemostasis market forecast outlook for 2025-2034?
- What are the regional markets covered in the EMR report?
- What is market segmentation based on product type?
- How is the market segmented based on the application?
- Who are the end-users in the market?
- What are the major factors aiding the global hemostasis market demand?
- How has the market performed so far and how is it anticipated to perform in the coming years?
- What are the market's major drivers, opportunities, and restraints?
- Which regional market is expected to lead the market share in the forecast period?
- Which country is expected to experience expedited growth during the forecast period?
- What are the major global hemostasis market trends?
- Which product type will dominate the market share?
- Which application is poised to lead the market share?
- Which end-user will lead the market?
- Who are the key players involved in the global hemostasis market?
- What is the patent landscape of the market?
- What are the current unmet needs and challenges in the market?
- How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?
Table of Contents
400 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Global Hemostasis Market Overview
- 3.1 Global Hemostasis Market Historical Value (2018-2024)
- 3.2 Global Hemostasis Market Forecast Value (2025-2034)
- 4 Vendor Positioning Analysis
- 4.1 Key Vendors
- 4.2 Prospective Leaders
- 4.3 Niche Leaders
- 4.4 Disruptors
- 5 Global Hemostasis Market Landscape
- 5.1 Global Hemostasis Market: Developers Landscape
- 5.1.1 Analysis by Year of Establishment
- 5.1.2 Analysis by Company Size
- 5.1.3 Analysis by Region
- 5.2 Global Hemostasis Market: Product Landscape
- 5.2.1 Analysis by Product Type
- 5.2.2 Analysis by Application
- 6 Global Hemostasis Market Dynamics
- 6.1 Market Drivers and Constraints
- 6.2 SWOT Analysis
- 6.2.1 Strengths
- 6.2.2 Weaknesses
- 6.2.3 Opportunities
- 6.2.4 Threats
- 6.3 PESTEL Analysis
- 6.3.1 Political
- 6.3.2 Economic
- 6.3.3 Social
- 6.3.4 Technological
- 6.3.5 Legal
- 6.3.6 Environment
- 6.4 Porter’s Five Forces Model
- 6.4.1 Bargaining Power of Suppliers
- 6.4.2 Bargaining Power of Buyers
- 6.4.3 Threat of New Entrants
- 6.4.4 Threat of Substitutes
- 6.4.5 Degree of Rivalry
- 6.5 Key Demand Indicators
- 6.6 Key Price Indicators
- 6.7 Industry Events, Initiatives, and Trends
- 6.8 Value Chain Analysis
- 7 Global Hemostasis Market Segmentation (218-2034)
- 7.1 Global Hemostasis Market (2018-2034) by Product Type
- 7.1.1 Market Overview
- 7.1.2 Topical Hemostasis Products
- 7.1.2.1 Gelatin-based Hemostats
- 7.1.2.2 Collagen-based Hemostats
- 7.1.2.3 ORC-based Hemostats
- 7.1.2.4 Polysaccharide-based
- 7.1.3 Infusible Hemostasis Products
- 7.1.3.1 Platelet Concentrate
- 7.1.3.2 Fresh Frozen Plasma
- 7.1.3.3 Factor VIII
- 7.1.3.4 Prothrombin
- 7.1.4 Advanced Hemostasis Products
- 7.1.4.1 Flowable
- 7.1.4.2 Thrombin
- 7.1.4.3 Synthetic Sealants
- 7.1.4.4 Fibrin
- 7.2 Global Hemostasis Market (2018-2034) by Application
- 7.2.1 Market Overview
- 7.2.2 General Surgery
- 7.2.3 Neurosurgery
- 7.2.4 Vascular Surgery
- 7.2.5 Cardiovascular Surgery
- 7.2.6 Others
- 7.3 Global Hemostasis Market (2018-2034) by End User
- 7.3.1 Market Overview
- 7.3.2 Hospitals
- 7.3.3 Specialty Clinics
- 7.3.4 Ambulatory Surgical Centers
- 7.3.5 Others
- 7.4 Global Hemostasis Market (2018-2034) by Region
- 7.4.1 Market Overview
- 7.4.2 North America
- 7.4.3 Europe
- 7.4.4 Asia Pacific
- 7.4.5 Latin America
- 7.4.6 Middle East and Africa
- 8 North America Hemostasis Market (218-2034)
- 8.1 North America Hemostasis Market (2018-2034) by Product Type
- 8.1.1 Market Overview
- 8.1.2 Topical Hemostasis Products
- 8.1.2.1 Gelatin-based Hemostats
- 8.1.2.2 Collagen-based Hemostats
- 8.1.2.3 ORC-based Hemostats
- 8.1.2.4 Polysaccharide-based
- 8.1.3 Infusible Hemostasis Products
- 8.1.3.1 Platelet Concentrate
- 8.1.3.2 Fresh Frozen Plasma
- 8.1.3.3 Factor VIII
- 8.1.3.4 Prothrombin
- 8.1.4 Advanced Hemostasis Products
- 8.1.4.1 Flowable
- 8.1.4.2 Thrombin
- 8.1.4.3 Synthetic Sealants
- 8.1.4.4 Fibrin
- 8.2 North America Hemostasis Market (2018-2034) by Application
- 8.2.1 Market Overview
- 8.2.2 General Surgery
- 8.2.3 Neurosurgery
- 8.2.4 Vascular Surgery
- 8.2.5 Cardiovascular Surgery
- 8.2.6 Others
- 8.3 North America Hemostasis Market (2018-2034) by End User
- 8.3.1 Market Overview
- 8.3.2 Hospitals
- 8.3.3 Specialty Clinics
- 8.3.4 Ambulatory Surgical Centers
- 8.3.5 Others
- 8.4 North America Hemostasis Market (2018-2034) by Country
- 8.4.1 United States of America
- 8.4.2 Canada
- 9 Europe Hemostasis Market (218-2034)
- 9.1 Europe Hemostasis Market (2018-2034) by Product Type
- 9.1.1 Market Overview
- 9.1.2 Topical Hemostasis Products
- 9.1.2.1 Gelatin-based Hemostats
- 9.1.2.2 Collagen-based Hemostats
- 9.1.2.3 ORC-based Hemostats
- 9.1.2.4 Polysaccharide-based
- 9.1.3 Infusible Hemostasis Products
- 9.1.3.1 Platelet Concentrate
- 9.1.3.2 Fresh Frozen Plasma
- 9.1.3.3 Factor VIII
- 9.1.3.4 Prothrombin
- 9.1.4 Advanced Hemostasis Products
- 9.1.4.1 Flowable
- 9.1.4.2 Thrombin
- 9.1.4.3 Synthetic Sealants
- 9.1.4.4 Fibrin
- 9.2 Europe Hemostasis Market (2018-2034) by Application
- 9.2.1 Market Overview
- 9.2.2 General Surgery
- 9.2.3 Neurosurgery
- 9.2.4 Vascular Surgery
- 9.2.5 Cardiovascular Surgery
- 9.2.6 Others
- 9.3 Europe Hemostasis Market (2018-2034) by End User
- 9.3.1 Market Overview
- 9.3.2 Hospitals
- 9.3.3 Specialty Clinics
- 9.3.4 Ambulatory Surgical Centers
- 9.3.5 Others
- 9.4 Europe Hemostasis Market (2018-2034) by Country
- 9.4.1 United Kingdom
- 9.4.2 Germany
- 9.4.3 France
- 9.4.4 Italy
- 9.4.5 Others
- 10 Asia Pacific Hemostasis Market (218-2034)
- 10.1 Asia Pacific Hemostasis Market (2018-2034) by Product Type
- 10.1.1 Market Overview
- 10.1.2 Topical Hemostasis Products
- 10.1.2.1 Gelatin-based Hemostats
- 10.1.2.2 Collagen-based Hemostats
- 10.1.2.3 ORC-based Hemostats
- 10.1.2.4 Polysaccharide-based
- 10.1.3 Infusible Hemostasis Products
- 10.1.3.1 Platelet Concentrate
- 10.1.3.2 Fresh Frozen Plasma
- 10.1.3.3 Factor VIII
- 10.1.3.4 Prothrombin
- 10.1.4 Advanced Hemostasis Products
- 10.1.4.1 Flowable
- 10.1.4.2 Thrombin
- 10.1.4.3 Synthetic Sealants
- 10.1.4.4 Fibrin
- 10.2 Asia Pacific Hemostasis Market (2018-2034) by Application
- 10.2.1 Market Overview
- 10.2.2 General Surgery
- 10.2.3 Neurosurgery
- 10.2.4 Vascular Surgery
- 10.2.5 Cardiovascular Surgery
- 10.2.6 Others
- 10.3 Asia Pacific Hemostasis Market (2018-2034) by End User
- 10.3.1 Market Overview
- 10.3.2 Hospitals
- 10.3.3 Specialty Clinics
- 10.3.4 Ambulatory Surgical Centers
- 10.3.5 Others
- 10.4 Asia Pacific Hemostasis Market (2018-2034) by Country
- 10.4.1 China
- 10.4.2 Japan
- 10.4.3 India
- 10.4.4 ASEAN
- 10.4.5 Australia
- 10.4.6 Others
- 11 Latin America Hemostasis Market (218-2034)
- 11.1 Latin America Hemostasis Market (2018-2034) by Product Type
- 11.1.1 Market Overview
- 11.1.2 Topical Hemostasis Products
- 11.1.2.1 Gelatin-based Hemostats
- 11.1.2.2 Collagen-based Hemostats
- 11.1.2.3 ORC-based Hemostats
- 11.1.2.4 Polysaccharide-based
- 11.1.3 Infusible Hemostasis Products
- 11.1.3.1 Platelet Concentrate
- 11.1.3.2 Fresh Frozen Plasma
- 11.1.3.3 Factor VIII
- 11.1.3.4 Prothrombin
- 11.1.4 Advanced Hemostasis Products
- 11.1.4.1 Flowable
- 11.1.4.2 Thrombin
- 11.1.4.3 Synthetic Sealants
- 11.1.4.4 Fibrin
- 11.2 Latin America Hemostasis Market (2018-2034) by Application
- 11.2.1 Market Overview
- 11.2.2 General Surgery
- 11.2.3 Neurosurgery
- 11.2.4 Vascular Surgery
- 11.2.5 Cardiovascular Surgery
- 11.2.6 Others
- 11.3 Latin America Hemostasis Market (2018-2034) by End User
- 11.3.1 Market Overview
- 11.3.2 Hospitals
- 11.3.3 Specialty Clinics
- 11.3.4 Ambulatory Surgical Centers
- 11.3.5 Others
- 11.4 Latin America Hemostasis Market (2018-2034) by Country
- 11.4.1 Brazil
- 11.4.2 Argentina
- 11.4.3 Mexico
- 11.4.4 Others
- 12 Middle East and Africa Hemostasis Market (218-2034)
- 12.1 Middle East & Africa Hemostasis Market (2018-2034) by Product Type
- 12.1.1 Market Overview
- 12.1.2 Topical Hemostasis Products
- 12.1.2.1 Gelatin-based Hemostats
- 12.1.2.2 Collagen-based Hemostats
- 12.1.2.3 ORC-based Hemostats
- 12.1.2.4 Polysaccharide-based
- 12.1.3 Infusible Hemostasis Products
- 12.1.3.1 Platelet Concentrate
- 12.1.3.2 Fresh Frozen Plasma
- 12.1.3.3 Factor VIII
- 12.1.3.4 Prothrombin
- 12.1.4 Advanced Hemostasis Products
- 12.1.4.1 Flowable
- 12.1.4.2 Thrombin
- 12.1.4.3 Synthetic Sealants
- 12.1.4.4 Fibrin
- 12.2 Middle East & Africa Hemostasis Market (2018-2034) by Application
- 12.2.1 Market Overview
- 12.2.2 General Surgery
- 12.2.3 Neurosurgery
- 12.2.4 Vascular Surgery
- 12.2.5 Cardiovascular Surgery
- 12.2.6 Others
- 12.3 Middle East and Africa Hemostasis Market (2018-2034) by End User
- 12.3.1 Market Overview
- 12.3.2 Hospitals
- 12.3.3 Specialty Clinics
- 12.3.4 Ambulatory Surgical Centers
- 12.3.5 Others
- 12.4 Middle East and Africa Hemostasis Market (2018-2034) by Country
- 12.4.1 Saudi Arabia
- 12.4.2 United Arab Emirates
- 12.4.3 Nigeria
- 12.4.4 South Africa
- 12.4.5 Others
- 13 Regulatory Framework
- 13.1 Regulatory Overview
- 13.2 US FDA
- 13.3 EU EMA
- 13.4 INDIA CDSCO
- 13.5 JAPAN PMDA
- 13.6 Others
- 14 Patent Analysis
- 14.1 Analysis by Type of Patent
- 14.2 Analysis by Publication Year
- 14.3 Analysis by Issuing Authority
- 14.4 Analysis by Patent Age
- 14.5 Analysis by CPC Analysis
- 14.6 Analysis by Patent Valuation
- 15 Grants Analysis
- 15.1 Analysis by Year
- 15.2 Analysis by Amount Awarded
- 15.3 Analysis by Issuing Authority
- 15.4 Analysis by Grant Application
- 15.5 Analysis by Funding Institute
- 15.6 Analysis by NIH Departments
- 15.7 Analysis by Recipient Organization
- 16 Funding and Investment Analysis
- 16.1 Analysis by Funding Instances
- 16.2 Analysis by Drug Type of Funding
- 16.3 Analysis by Funding Amount
- 16.4 Analysis by Leading Players
- 16.5 Analysis by Leading Investors
- 16.6 Analysis by Geography
- 17 Strategic Initiatives
- 17.1 Analysis by Partnership Instances
- 17.2 Analysis by Type of Partnership and Collaborations
- 17.3 Analysis by Joint Ventures
- 17.4 Analysis by Leading Players
- 17.5 Analysis by Geography
- 17.6 Analysis by Merger & Acquisitions
- 18 Supplier Landscape
- 18.1 Market Share Analysis, By Region (Top 5 Companies)
- 18.1.1 Market Share Analysis: Global
- 18.1.2 Market Share Analysis: North America
- 18.1.3 Market Share Analysis: Europe
- 18.1.4 Market Share Analysis: Asia Pacific
- 18.1.5 Market Share Analysis: Others
- 18.2 Medtronic PLC
- 18.2.1 Financial Analysis
- 18.2.2 Product Portfolio
- 18.2.3 Demographic Reach and Achievements
- 18.2.4 Company News and Development
- 18.2.5 Certifications
- 18.3 Johnson & Johnson Inc.
- 18.3.1 Financial Analysis
- 18.3.2 Product Portfolio
- 18.3.3 Demographic Reach and Achievements
- 18.3.4 Company News and Development
- 18.3.5 Certifications
- 18.4 Baxter International Inc.
- 18.4.1 Financial Analysis
- 18.4.2 Product Portfolio
- 18.4.3 Demographic Reach and Achievements
- 18.4.4 Company News and Development
- 18.4.5 Certifications
- 18.5 Pfizer
- 18.5.1 Financial Analysis
- 18.5.2 Product Portfolio
- 18.5.3 Demographic Reach and Achievements
- 18.5.4 Company News and Development
- 18.5.5 Certifications
- 18.6 BD
- 18.6.1 Financial Analysis
- 18.6.2 Product Portfolio
- 18.6.3 Demographic Reach and Achievements
- 18.6.4 Company News and Development
- 18.6.5 Certifications
- 18.7 B. Braun SE
- 18.7.1 Financial Analysis
- 18.7.2 Product Portfolio
- 18.7.3 Demographic Reach and Achievements
- 18.7.4 Company News and Development
- 18.7.5 Certifications
- 18.8 Tricol Biomedical
- 18.8.1 Financial Analysis
- 18.8.2 Product Portfolio
- 18.8.3 Demographic Reach and Achievements
- 18.8.4 Company News and Development
- 18.8.5 Certifications
- 18.9 Boston Scientific Corporation
- 18.9.1 Financial Analysis
- 18.9.2 Product Portfolio
- 18.9.3 Demographic Reach and Achievements
- 18.9.4 Company News and Development
- 18.9.5 Certifications
- 18.10 Cura Medical
- 18.10.1 Financial Analysis
- 18.10.2 Product Portfolio
- 18.10.3 Demographic Reach and Achievements
- 18.10.4 Company News and Development
- 18.10.5 Certifications
- 18.11 Teleflex Incorporated
- 18.11.1 Financial Analysis
- 18.11.2 Product Portfolio
- 18.11.3 Demographic Reach and Achievements
- 18.11.4 Company News and Development
- 18.11.5 Certifications
- 19 Global Hemostasis Market – Distribution Model (Additional Insight)
- 19.1 Overview
- 19.2 Potential Distributors
- 19.3 Key Parameters for Distribution Partner Assessment
- 20 Key Opinion Leaders (KOL) Insights (Additional Insight)
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
